Insmed Inc (INSM)

[rfoable1]

GS,
They are demonstrating that they are aware of the concerns about hypoglycemia with Increlex.

They are trying to broadcast that the 1.8% increase in hypos does not meet their statistical criteria for blaming it on Increlex. (The null hypothesis, that there is no correlation, was not rejected)

I doubt we are going to have any ability to dig up how they composed the sample population, but using 22 patients makes it a fairly low power calculation anyway. If they had the same result from all their 151 patients, it would have a lot more power.

A piece of trivia: Has anyone noticed the odd coincidence that the total number of patients on Increlex they reported matches the number of their "increased anabolic response" patent? ('151)

cheers